Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?

NCT ID NCT07657325

Recruiting now Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. About 110 adults with high-risk renal cell carcinoma will receive toripalimab after surgery and be followed for cancer recurrence and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (an immunotherapy drug)
What this could lead to: If successful, this could show that toripalimab helps prevent kidney cancer from returning after surgery, and that a blood test (MRD) can identify which patients need it most.
What could go wrong: This is a single-arm study with no placebo group, so results may be less definitive. The drug may cause immune-related side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

Changyi Quan
RECRUITING

Tianjin, Tianjin Municipality, 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.